Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: A report from the Children's Oncology Group

Blood

Volumn 122, Issue 4, 2013, Pages 507-514

  Salzer, Wanda L ^a   Asselin, Barbara ^b   Supko, Jeffrey G ^c   Devidas, Meenakshi ^d   Kaiser, Nicole A ^e   Plourde, Paul ^f   Winick, Naomi J ^g   Reaman, Gregory H ^h   Raetz, Elizabeth ⁱ   Carroll, William L ^j   Hunger, Stephen P ^e,k  

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e CHILDREN S HOSPITAL COLORADO   (United States)

^f EUSA Pharma   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁱ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^j NEW YORK UNIVERSITY   (United States)

^k Children's Hospital Colorado   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLEEDING; CHILD; DEATH; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENZYME ACTIVITY; ERWINIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; KETOACIDOSIS; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; SIDE EFFECT; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG SUBSTITUTION; ENZYMOLOGY; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PRESCHOOL CHILD; REMISSION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; ERWINIA; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MEDICAL ONCOLOGY; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION;

EID: 84886925289     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-480822     Document Type: Article

References (50)

1. Dolowy WC, Henson D, Cornet J., Sellin H. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer. 1966; 19(12): 1813-1819.
2. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008; 22(9): 1665-1679.
3. Capizzi RL, Bertino JR, Skeel R.T., et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med. 1971; 74(6): 893-901.
4. Jaffe N, Traggis D, Das L., Moloney WC, Hann HW, Kim BS, Nair R. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res. 1971; 31(7): 942-949.
5. Nesbit ME, Ertel I, Hammond GD. L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group. Cancer Treat Rep. 1981; 65(SUPPL. 4): 101-107. (Pubitemid 13243414)
6. Sutow WW, Garcia F, Starling K.A., Williams TE, Lane DM, Gehan EA. L-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group. Cancer. 1971; 28(4): 819-824.
7. Tallal L, Tan C, Oettgen H., et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer. 1970; 25(2): 306-320.
8. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998; 339(9): 605-615. (Pubitemid 28385659)
9. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354(2): 166-178. (Pubitemid 43076714)
10. Clavell LA, Gelber RD, Cohen H.J., et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986; 315(11): 657-663. (Pubitemid 16055930)
11. Jones B, Holland JF, Glidewell O, et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol. 1977; 3(4): 387-400. (Pubitemid 8235411)
12. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008; 371(9617): 1030-1043. (Pubitemid 351389536)
13. Ertel IJ, Nesbit ME, Hammond D, Weiner J., Sather H. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group. Cancer Res. 1979; 39(10): 3893-3896. (Pubitemid 10242204)
14. Nachman JB, Sather HN, Sensel M.G., et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998; 338(23): 1663-1671. (Pubitemid 28267911)
15. Amylon MD, Shuster J, Pullen J., et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999; 13(3): 335-342. (Pubitemid 29108071)
16. Schrappe M, Camitta B, Pui C-H. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000; 14(12): 2193-2194. (Pubitemid 32043589)
17. Asselin BL, Whitin JC, Coppola D.J., Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993; 11(9): 1780-1786. (Pubitemid 23277332)
18. Albertsen BK, Schrøder H, Ingerslev J., et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol. 2001; 115(4): 983-990. (Pubitemid 34042920)
19. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005; 44(4): 367-393. (Pubitemid 40663683)
20. Avramis VI, Spence SA. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol. 2007; 29(4): 239-247. (Pubitemid 46597688)
21. Panetta JC, Gajjar A, Hijiya N., et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009; 86(6): 651-658.
22. Avramis VI, Sencer S, Periclou A.P., et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002; 99(6): 1986-1994. (Pubitemid 34525479)
23. Boos J, Werber G, Ahlke E., et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996; 32A(9): 1544-1550. (Pubitemid 26279122)
24. Salzer W, Asselin B, Supko J., et al. Administration of Erwinia Asparaginase Following Allergy to PEG-Asparaginase In Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG). ASH Annual Meeting Abstracts. 2010; 116(21): 2134.
25. Vrooman LM, Supko JG, Neuberg D.S., et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010; 54(2): 199-205.
26. Rescigno A, Segre G. Drug and Tracer Kinetics. Waltham, MA: Blaisdell Publishing Co.; 1966: 16-21
27. Onuma T, Waligunda J, Holland JF. Amino acid requirements in vitro of human leukemic cells. Cancer Res. 1971; 31(11): 1640-1644.
28. Ho DHW, Whitecar JP Jr, Luce JK, Frei E III. L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res. 1970; 30(2): 466-472.
29. Broome JD. Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells. J Exp Med. 1968; 127(6): 1055-1072.
30. Riccardi R, Holcenberg JS, Glaubiger D.L., Wood JH, Poplack DG. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 1981; 41(11 Pt 1): 4554-4558. (Pubitemid 12201374)
31. Ahlke E, Nowak-Göttl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 1997; 96(4): 675-681. (Pubitemid 27115859)
32. Asselin BL, Ryan D, Frantz C.N., Bernal SD, Leavitt P, Sallan SE, Cohen HJ. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989; 49(15): 4363-4368. (Pubitemid 19207288)
33. Tsurusawa M, Chin M, Iwai A., et al.; Japanese Children's Cancer and Leukemia Study Group. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment. Cancer Chemother Pharmacol. 2004; 53(3): 204-208. (Pubitemid 38293717)
34. Asselin BL, Lorenson MY, Whitin J.C., Coppola DJ, Kende AS, Blakley RL, Cohen HJ. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res. 1991; 51(24): 6568-6573.
35. Gentili D, Zucchetti M, Conter V., Masera G, D'Incalci M. Determination of L-asparagine in biological samples in the presence of L-asparaginase. J Chromatogr B Biomed Appl. 1994; 657(1): 47-52. (Pubitemid 24220734)
36. Gentili D, Conter V, Rizzari C., et al. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol. 1996; 7(7): 725-730. (Pubitemid 26323546)
37. Dibenedetto SP, Di Cataldo A, Ragusa R, Meli C., Lo Nigro L. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. 1995; 13(2): 339-344.
38. Woo MH, Hak LJ, Storm M.C., et al. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol. 1999; 17(5): 1568-1573. (Pubitemid 29220866)
39. Silverman LB, Gelber RD, Dalton V.K., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001; 97(5): 1211-1218. (Pubitemid 32183741)
40. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007; 109(3): 896-904. (Pubitemid 46220632)
41. Sallan SE, Hitchcock-Bryan S, Gelber R., Cassady JR, Frei E III, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983; 43(11): 5601-5607. (Pubitemid 14230187)
42. Avramis VI, Avramis EV, Hunter W, Long MC. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res. 2009; 29(1): 299-302.
43. Tiwari PN, Zielinski M, Quinn J.J., et al. Assessment of Anti-Asparaginase (ASNase) Antibodies (Ab) and ASNase Activity after Suspected Clinical Allergy. ASH Annual Meeting Abstracts. 2006; 108(11): 1878.
44. Salzer W, Seibel N, Smith M. Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Opin Biol Ther. 2012; 12(10): 1407-1414.
45. Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011; 117(2): 238-249.
46. Duval M, Suciu S, Ferster A., et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002; 99(8): 2734-2739. (Pubitemid 34525359)
47. Vieira Pinheiro J.P., Ahlke E, Nowak-Göttl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol. 1999; 104(2): 313-320. (Pubitemid 29083340)
48. Rizzari C, Valsecchi MG, Aricò M, et al; Associazione Italiano Ematologia Oncologia Pediatrica. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study - a report from the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin Oncol. 2001; 19(5): 1297-1303. (Pubitemid 32202533)
49. Beard ME, Crowther D, Galton D.A., et al. L-asparaginase in treatment of acute leukaemia and lymphosarcoma. BMJ. 1970; 1(5690): 191-195.
50. Byron PR, Notari RE. Critical analysis of "flip-flop" phenomenon in two-compartment pharmacokinetic model. J Pharm Sci. 1976; 65(8): 1140-1144.